XOMA Royalty (XOMA) Q4 2025 earnings review
A Profitable Turnaround Built on Royalties and Financial Engineering
XOMA Royalty flipped the switch to profitability in FY25, reversing a year of heavy losses to post $31.7M in Net Income. The primary driver was a 68% surge in royalty receipts, anchored by VABYSMO and the newly launched OJEMDA. However, investors must look under the hood: a massive portion of this year's net income came from $21.2M in non-cash acquisition gains. Furthermore, severe Phase 3 clinical failures from partners Rezolute and Gossamer Bio in Q4/Q1 cast a long shadow over the $1.1B potential milestone pool. The business model is working, but the earnings quality is lower than the headline numbers suggest.
🐂 Bull Case
Total cash receipts hit $50.5M for the year, with royalties jumping 68%. VABYSMO alone brought in $22.5M in the first three quarters, providing a predictable, highly profitable cash flow baseline.
Management executed a brilliant aggregator strategy: they acquired 7 companies, added 22 assets to the portfolio, and somehow walked away with $11.7M in net non-dilutive capital and massive Section 174 tax deductions.
🐻 Bear Case
The narrative that XOMA's portfolio is 'de-risked' by late-stage assets took a severe hit. Partner Rezolute's ersodetug missed statistical significance in congenital HI, and Gossamer Bio's seralutinib missed its alpha threshold in PAH. These failures instantly vaporize expected milestone revenues.
While FY25 Net Income was $31.7M, Operating Income was only $11.4M. The bottom line was heavily inflated by $21.2M in accounting gains from acquisitions, masking the underlying cash-generation capacity.
⚖️ Verdict: ⚪
Neutral. The core royalty engine is Accelerating beautifully, and the M&A playbook is highly creative. However, the reliance on unpredictable partner milestones and recent Phase 3 blowups highlight the strict binary risks inherent in the biotech aggregator model.
Key Themes
Core Royalty Engine Reversing Cash Burn
XOMA's transition to a commercial-stage aggregator is paying off. Royalty receipts jumped to $33.6M in FY25 (up from $20.0M in FY24), fundamentally Reversing the company's cash burn profile. VABYSMO and OJEMDA are doing the heavy lifting, covering the company's fixed operating costs and allowing excess cash to be funneled into stock buybacks ($16M deployed in FY25).
Capitalizing on the Biotech Funding Winter
Macro environment: The prolonged drought in biotech capital markets has created a buyer's market for XOMA. Cash-starved biotechs are offloading legacy assets and platforms for non-dilutive capital. XOMA completed 7 acquisitions in 2025, deploying just $25M while securing ~25% economic interests in up to $1.1B of milestones.
Phase 3 Misses Contradict 'De-Risked' Narrative
Management frequently touts having 14 programs in registrational studies as a de-risked catalyst pool. The data severely contradicts this optimism: Rezolute's Phase 3 ersodetug trial failed to show statistical significance due to a 'pronounced study effect,' and Gossamer Bio's Phase 3 seralutinib trial missed its prespecified alpha threshold. These failures highlight that late-stage biotech assets still carry massive binary risk, threatening XOMA's projected milestone runway.
Platform Technology Expansion
Innovation focus: XOMA is moving beyond single-asset royalties by acquiring underlying platform technologies. Through recent M&A, they acquired Generation Bio's ctLNP delivery platform and HilleVax's Norovirus platform. XOMA is now eligible for 25-70% of proceeds from any future out-licensing of these foundational technologies, creating a massive, albeit highly speculative, new revenue vertical.
Janssen Litigation Dragging Operating Leverage
G&A expenses remain stubbornly high, Decelerating slightly in growth but still consuming $36.1M in FY25. A notable contributor is the ongoing litigation against Janssen Biotech over the commercialization of TREMFYA. XOMA incurred an additional $1.1M in legal fees in 2025 and explicitly warned that these professional service costs will continue indefinitely, pressuring operating margins.
Other KPIs
Reversing. A massive improvement from the $40.0M operating loss in FY24. However, it is vital to note that Operating Expenses still eclipse total cash receipts from the portfolio, meaning the company remains heavily reliant on lumpy milestone payments and accounting gains to show GAAP profitability.
Reversing. Cash provided by operating activities turned positive at $2.9M, compared to a $13.7M burn in 2024. This marks a critical inflection point for the business model, theoretically allowing the company to fund its own acquisitions and dividends without tapping equity markets.
Guidance
Accelerating. While XOMA does not issue direct revenue guidance, partner Day One expects rapid growth for OJEMDA. With XOMA holding a mid-single digit royalty, the $237.5M midpoint implies roughly $11.8M in highly-predictable royalty revenue strictly from this single asset in 2026.
Stable. The company expects EMA decisions for OJEMDA and MIPLYFFA, alongside regulatory updates for ersodetug and seralutinib. However, given the recent clinical data misses on the latter two, the probability of milestone payouts tied to these specific regulatory events has plummeted.
Key Questions
Impact of Recent Phase 3 Failures
Given the recent statistical misses by Gossamer Bio and Rezolute, how much of the modeled $1.1B in potential milestone payments do you now consider functionally impaired or delayed?
Janssen Litigation Timeline
G&A is being weighed down by $1.1M in litigation costs against Janssen. Is there a projected timeline for a settlement or court decision, and what is the ceiling on legal expenses you are willing to tolerate?
Platform Technology Monetization
You acquired the ctLNP delivery platform and Norovirus platform this year. What is the active strategy and timeline for out-licensing these technologies to generate cash, versus holding them passively?